{
  "abstract": "We thank Belančić and colleagues1 for their thoughtful and constructive comments on our recent publication2 on the stability of ready-to-administer alglucosidase alfa infusions. We appreciate the recognition of the clinical relevance of our findings and the opportunity to address the important points raised.",
  "authors": [
    {
      "affiliations": [
        "Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"
      ],
      "name": "Ina Barzel"
    },
    {
      "affiliations": [
        "Department of Outpatient Pharmacy, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"
      ],
      "name": "Jan Dietert Brugma"
    },
    {
      "affiliations": [
        "Department of Clinical Genetics, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"
      ],
      "name": "Edwin H Jacobs"
    },
    {
      "affiliations": [
        "Department of Clinical Genetics, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"
      ],
      "name": "Marianne Hoogeveen-Westerveld"
    },
    {
      "affiliations": [
        "Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"
      ],
      "name": "Hugo M van der Kuy"
    },
    {
      "affiliations": [
        "Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"
      ],
      "name": "Tim Preijers"
    }
  ],
  "title": "Response to: Correspondence on ‘Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements’ by Barzel et al",
  "uid": "0ca4ca71-fbeb-5a13-a069-4f24ef6a289e"
}